Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Unknown 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Stomach Neoplasms 128Esophageal Neoplasms 127Esophageal Squamous Cell Carcinoma 77Adenocarcinoma Of Esophagus 36Pancreatic Neoplasms 30Colorectal Neoplasms 25Carcinoma, Non-Small-Cell Lung 23Breast Neoplasms 22Neoplasms 21Neoplasm Metastasis 19Ovarian Neoplasms 16Melanoma 12Lung Neoplasms 11Carcinoma, Squamous Cell 11Parkinson Disease 4, Autosomal Dominant Lewy Body 10Adenocarcinoma 10Endometrial Neoplasms 9Carcinoma, Renal Cell 9Advanced Gastric Cancer 9Squamous Cell Carcinoma of Head and Neck 8Peritoneal Neoplasms 8Colonic Neoplasms 8Carcinoma, Ovarian Epithelial 8Anus Neoplasms 8Digestive System Neoplasms 7Prostatic Neoplasms 6Cholangiocarcinoma 6Biliary Tract Neoplasms 6Uterine Cervical Neoplasms 5Sarcoma 5

Interventions

Paclitaxel 2lenvatinib 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Advanced Gastric or Gastroesophageal Junction Adenocarcinoma × Paclitaxel × Gastrointestinal × Clear all
NCT05585580 2026-05-26

Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy

Qilu Hospital of Shandong University

Phase 2 Active not recruiting
59 enrolled
Gastrointestinal

Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

NCT04435652 2020-06-17

A Study of QL1604 Plus Nab-paclitaxel Versus Paclitaxel in Subjects With Advanced Gastric Cancer.

Qilu Pharmaceutical Co., Ltd.

Phase 2/3 Unknown
492 enrolled
Gastrointestinal

Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡